Arcede Pharma develops RCD405, a dual-action drug candidate for the treatment of COPD and severe asthma. The company is underway with the final part of the preclinical development, where it is waiting for final results from the toxicology program. Recently, the team was expanded with two scientific advisors, both leading experts in the respiratory field. In an interview in connection with the BioStock Investor Meeting, Arcede Pharma’s CEO Mia Lundblad gave an update.
Notes
Camurus CAM2029 shows efficacy in polycystic liver disease
Cantargia secures SEK 50 million in loan facility
Oncoinvent reports positive phase I/IIa data for Radspherin
Eli Lilly acquires Verve Therapeutics for $1,3 billion
Alzinova appoints Worldwide Clinical Trials as CRO
NEWSLETTER
NEWS
Alzinova is pursuing partnerships at BIO
Mentice implements organizational changes and plans capital raising
Nosa Plugs acquires Pharmacure and aims for SEK 50 million in sales
Upcoming events!
Investing in Life Science
We cover early-stage, growth-stage and late-stage investments. From business angels and seed investors driving medical breakthroughs, to investments empowering promising...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
Bispecific and Chinese the new black in cancer
The venture capital cycle is complete – we are back where we started
